Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.42 |
| ▸ | ADRB3 | P13945 | 6/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.42 |
| ▸ | CFD | P00746 | 2/20 | 0.41 |
| ▸ | MYC | P01106 | 1/20 | 0.41 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.41 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20242123 | 0.98 | ALDH1A1 (0.54) | ALDH1A1ARKDM4EGLAIRAK4 | |
| SCHEMBL21607500 | 0.86 | PTGDR2 (0.47) | ALDH1A1ARIRAK4PTGDR2POLB | |
| SCHEMBL20107872 | 0.83 | ALDH1A1 (0.41) | ALDH1A1KDM4EGLAPTGDR2CFD | |
| SCHEMBL29816552 | 0.83 | ALDH1A1 (0.41) | ALDH1A1KDM4EGLAPTGDR2CFD | |
| SCHEMBL8512059 | 0.82 | NR4A2 (0.47) | ALDH1A1ARKDM4EIRAK4HSD17B10 | |
| SCHEMBL18309195 | 0.82 | ALDH1A1 (0.57) | ALDH1A1KDM4EIRAK4ADRB3ADRB1 | |
| SCHEMBL20107592 | 0.81 | RORC (0.42) | ALDH1A1KDM4EGLACFDMYC | |
| SCHEMBL21853435 | 0.81 | RORC (0.42) | ALDH1A1KDM4EGLACFDMYC | |
| SCHEMBL29512881 | 0.81 | RORC (0.42) | ALDH1A1KDM4EGLACFDMYC | |
| SCHEMBL5236256 | 0.81 | KDM4E (0.44) | ALDH1A1KDM4EGLACFDMYC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040249188-A1 | Process for the preparation of 3-ethoxy-4-(alkoxy carbonyl)-phenyl acetic acid. (an intermediate of repaglinide) | DR. REDDY'S LABORATORIES LIMITED | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040249188-A1 | Process for the preparation of 3-ethoxy-4-(alkoxy carbonyl)-phenyl acetic acid. (an intermediate of repaglinide) | ALDH1A1, ADRM1, ALDH7A1 | ALDH1A1 1/4885AR 340/4885KDM4E 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.